EpCAM and p53 Expressions in Infiltrating Duct Carcinoma of the Breast

Trial Title: EpCAM and p53 Expressions in Infiltrating Duct Carcinoma of the Breast

NCT ID: NCT05703815

Condition: Invasive Breast Cancer

Conditions: Official terms:
Carcinoma, Ductal
Breast Neoplasms

Conditions: Keywords:
EpCAM, P53 , IDC

Study type: Observational

Overall status: Not yet recruiting

Study design:

Time perspective: Retrospective

Summary: Breast cancer represents the most frequently diagnosed cancer in women. It represents the 5th leading cause of cancer mortality all over the world. In Egypt, breast cancer represents the 2nd most diagnosed cancer among all population. But among Egyptian females it represents the 1st diagnosed cancer representing 32.4%. The main cause of death in breast cancer patients is tumor metastasis. Although only 5-10% of recently diagnosed breast cancer cases show metastasis to distant sites, but still there is a high risk for metastasis in patients with localized primary tumor following successful surgical management. Epithelial cell adhesion molecule (EpCAM) is a cell adhesion molecule. It modifies cadherin mediated cell adhesion and it induces epithelial cell migration and proliferation. Some authors elucidate that EpCAM is involved in metastasis. P53 is a known tumor suppressor gene involved in the control of cell cycle, DNA repair and apoptosis. It's one of the most mutated genes in cancer including breast cancer. Mutant p53 has a big role in tumor progression.

Criteria for eligibility:

Study pop:
formalin-fixed and paraffin embedded tissue blocks from 40 patients with breast cancer

Sampling method: Probability Sample
Criteria:
Inclusion Criteria: - Both incisional and excisional biopsy specimens. 2. All the studied cases include sufficient materials for the immunohistochemical study. 3. Complete clinical data. Exclusion Criteria: 1. Patients with recurrence of the primary tumor. 2. Patients with a history of preoperative chemotherapy and/or radiotherapy. 3. Insufficient or tiny tissue biopsies

Gender: Female

Minimum age: 20 Years

Maximum age: 80 Years

Healthy volunteers: No

Start date: January 2023

Completion date: March 2023

Lead sponsor:
Agency: Sohag University
Agency class: Other

Source: Sohag University

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05703815